IP Library Granted Patent US 10,010,631
Granted Patent B2
US 10,010,631 · App. 13/916,205 · Granted Jul 3, 2018

Ligands for imaging cardiac innervation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,010,631
App. No.
13/916,205
Granted
Jul 3, 2018
Kind
B2
Abstract

Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

Claims (79)

1. A compound of the structure:

or a salt thereof,

wherein n is 0;

A and R 2 are absent;

X, W, R and R 3 are hydrogen;

R 1 is NHC(═NH)NH 2 ;

Y is H, F, Cl, or Br; and

Z is OR 4 and R 4 is alkyl substituted with 18 F.

2. A method of imaging cardiac innervation comprising the steps of:

administering an effective amount of the compound of claim 1 or a salt thereof to a patient;

detecting radiation emitted by said compound; and

forming an image therefrom.

3. The compound of claim 1 , wherein the compound is a salt.

4. The compound of claim 1 , wherein the compound is a salt of a compound selected from the group consisting of:

5. A composition for imaging cardiac innervation comprising the compound of claim 4 , and optionally one or more excipients.

6. A method of imaging cardiac innervation comprising the steps of:

administering an effective amount of the compound of claim 4 to a patient;

detecting radiation emitted by said compound; and

forming an image therefrom.

7. The compound of claim 1 , wherein the compound is a salt of the compound:

8. The compound of claim 7 , wherein the salt has the structure N-[3-bromo-4(3-[18F]fluoropropoxy)-benzyl]-guanidine hydrochloride.

9. A composition for imaging cardiac innervation comprising the compound of claim 7 , and optionally one or more excipients.

10. A method of imaging cardiac innervation comprising the steps of:

administering an effective amount of the compound of claim 7 to a patient;

detecting radiation emitted by said compound; and

forming an image therefrom.

11. A composition for imaging cardiac innervation comprising the compound of claim 1 , and optionally one or more excipients.

12. A compound of the structure:

or a salt thereof,

wherein n is 1;

A is absent;

R 2 is hydrogen or OR 4 , wherein R 4 is H or alkyl;

X, W, R and R 3 are hydrogen;

R 1 is NHC(═NH)NH 2 ;

Y is H, F, Cl, or Br; and

Z is OR 4 , wherein R 4 is alkyl substituted with 18 F.

13. A compound of the structure:

or a salt thereof,

wherein n is 0 or 1;

A is absent;

R 2 , when present, is hydrogen or OR 4 , wherein R 4 is H or alkyl;

X, W, R and R 3 are hydrogen;

R 1 is NHC(═NH)NH 2 ;

Z is H, F, Cl, or Br; and

Y is OR 4 , wherein R 4 is alkyl substituted with 18 F.

14. A compound of the structure:

or a salt thereof,

wherein n is 0 or 1;

R is NR 4 C(═NR 5 )NHR 6 ;

R 1 is selected from the group consisting of H and alkyl (C 1 -C 4 );

when present, R 2 is H or OR 4

R 3 is H;

R 4 , R 5 , and R 6 are independently selected from the group consisting of H and alkyl (C 1 -C 8 ), wherein one or more R 4 -R 6 may be substituted with an imaging moiety;

A is absent;

W and X are hydrogen; and

Y and Z are independently selected from the group consisting of H, OR 4 , F, Cl, Br, and I,

wherein Y or Z is OR 4 and R 4 is alkyl substituted with 18 F.

15. The compound of claim 14 , wherein the compound has the structure:

or a salt thereof.

16. A method of imaging cardiac innervation comprising the steps of:

administering an effective amount of the compound of claim 12 or a salt thereof to a patient;

detecting radiation emitted by said compound; and

forming an image therefrom.

17. A method of imaging cardiac innervation comprising the steps of:

administering an effective amount of the compound of claim 13 or a salt thereof to a patient;

detecting radiation emitted by said compound; and

forming an image therefrom.

18. A method of imaging cardiac innervation comprising the steps of:

administering an effective amount of the compound of claim 15 or a salt thereof to a patient;

detecting radiation emitted by said compound; and

forming an image therefrom.

19. A method of imaging cardiac innervation comprising the steps of:

administering an effective amount of the compound of claim 14 or a salt thereof to a patient;

detecting radiation emitted by said compound; and

forming an image therefrom.

20. The compound of claim 13 , wherein n is 0.

21. The compound of claim 14 , wherein n is 0.

22. The compound of claim 13 , wherein n is 1.

23. The compound of claim 14 , wherein n is 1.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 062047/0925 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Jun 28, 2019
From: LANTHEUS MEDICAL IMAGING, INC.
To: WELLS FARGO BANK, N.A.
Reel/Frame 049628/0001 →
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2019
From: JPMORGAN CHASE BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 049623/0123 →
RELEASE OF SECURITY INTEREST IN CERTAIN PATENTS Recorded Mar 30, 2017
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: LANTHEUS HOLDINGS, INC.; LANTHEUS MEDICAL IMAGING, INC.; LANTHEUS MI REAL ESTATE, LLC
Reel/Frame 042115/0715 →
NOTICE OF SUCCESSION OF AGENCY Recorded Mar 30, 2017
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 042115/0769 →
MERGER Recorded Oct 23, 2015
From: ACP LANTERN ACQUISITION, INC.
To: BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC.
Reel/Frame 036862/0766 →
NUNC PRO TUNC ASSIGNMENT Recorded Oct 23, 2015
From: PUROHIT, AJAY; HARRIS, THOMAS D.; RADEKE, HEIKE S.; ROBINSON, SIMON P.; YU, MING; CASEBIER, DAVID S.; AZURE, MICHAEL T.
To: BRISTOL-MYERS SQUIBB PHARMA COMPANY
Reel/Frame 036932/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2015
From: BRISTOL-MYERS SQUIBB PHARMA COMPANY
To: ACP LANTERN ACQUISITION, INC.
Reel/Frame 036932/0413 →
CHANGE OF NAME Recorded Oct 23, 2015
From: BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 036942/0143 →
SECURITY AGREEMENT Recorded Jun 30, 2015
From: LANTHEUS MEDICAL IMAGING, INC.
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Reel/Frame 036013/0516 →
AMENDMENT NUMBER TWO Recorded Jun 30, 2015
From: LANTHEUS HOLDINGS, INC.; LANTHEUS MEDICAL IMAGING, INC.; LANTHEUS MI REAL ESTATE, LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 036039/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2013
From: PUROHIT, AJAY; HARRIS, THOMAS D.; RADEKE, HEIKE S.; ROBINSON, SIMON P.; YU, MING; AZURE, MICHAEL T.; CASEBIER, DAVID S.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 030785/0119 →
Cited By (1)
US 12,324,845